Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical firm, announced that CEO David Hering will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2022, at 4:25 p.m. GMT. The event will be accessible via a live webcast on the investor section of Invivyd’s website, with an archive available for 90 days post-presentation.
Invivyd focuses on developing antibodies to enhance immunity against serious viral respiratory diseases, including COVID-19. Its first candidate, NVD200, aims to prevent and treat COVID-19 using advanced antibody technology.
- None.
- None.
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 4:25 p.m. GMT.
A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation.
About Invivyd
(Nasdaq: IVVD)
Invivyd, formerly Adagio Therapeutics (Nasdaq: ADGI), is a biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. The company’s integrated discovery platform is generating a robust pipeline of products for use in both prevention and treatment of disease. NVD200, Invivyd’s first antibody combination product candidate for the prevention and treatment of COVID-19, includes a re-engineered version of adintrevimab, an investigational monoclonal antibody which demonstrated clinically meaningful results against multiple variants of concern in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19, prior to the emergence of Omicron. The safety and efficacy of adintrevimab have not been established. The company also has multiple discovery stage candidates for the prevention of seasonal influenza. Visit www.invivyd.com to learn more.
Contacts
Media Contact:
Tony Berry, Evoke Canale
774-317-0422
anthony.berry@evokegroup.com
Investor Contact:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
FAQ
When is David Hering speaking at the Jefferies London Healthcare Conference?
How can I watch Invivyd's CEO's presentation?
What is Invivyd's main focus in biopharmaceuticals?
What is NVD200 by Invivyd?
What technology does Invivyd use to develop its antibodies?
